Cargando…
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Cancer vaccines (CVs) represent a long-sought therapeutic and prophylactic immunotherapy strategy to obtain antigen (Ag)-specific T-cell responses and potentially achieve long-term clinical benefit. However, historically, most CV clinical trials have resulted in disappointing outcomes, despite promi...
Autores principales: | Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortes, J., Romero, P., Mittendorf, E.A., Disis, M.L., Curigliano, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420263/ https://www.ncbi.nlm.nih.gov/pubmed/34500046 http://dx.doi.org/10.1016/j.annonc.2021.08.2153 |
Ejemplares similares
-
1583P COVID-19 related risk in patients enrolled in early-phase clinical trials
por: D'Amico, P., et al.
Publicado: (2021) -
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
por: Crimini, Edoardo, et al.
Publicado: (2022) -
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023) -
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021) -
Revamp the NTP bioassay.
por: Shubik, P
Publicado: (1995)